Search

Search Constraints

You searched for: Author/Creator Jenkins, Kurt

Search Results

1. 568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates. (9th November 2020)

2. 568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates. (9th November 2020)

3. 587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models. (10th December 2020)

4. Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells. Issue 6 (21st June 2022)